CH
XFOR icon

CVI Holdings’s X4 Pharmaceuticals XFOR Stock Holding History

CVI Holdings’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-76,677
Closed -$4.46M – 250
2023
Q2 		$4.46M Buy
+76,677
New +$3.94M 4.69% 3
2023
Q1 		– Sell
-79,397
Closed -$2.37M – 443
2022
Q4 		$2.37M Buy
+79,397
New +$3.76M 0.3% 118

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TLP
Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CVI Holdings's XFOR Position: Q3 2023 in Review

CVI Holdings sold out of X4 Pharmaceuticals (XFOR) in Q3 2023, closing a stake of 76,677 shares — an estimated $4.46M sold.

CVI Holdings first reported a position in XFOR in Q4 2022 and held it in 2 quarters. The position peaked at $4.46M in Q2 2023. 91 funds tracked by Wall St. Rank hold XFOR as of Q3 2023.

  • CVI Holdings reported no remaining X4 Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • CVI Holdings sold 76,677 X4 Pharmaceuticals shares in Q3 2023, an estimated $4.46M.
  • CVI Holdings first reported a position in X4 Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • CVI Holdings's X4 Pharmaceuticals position peaked at $4.46M in Q2 2023.
  • 91 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q3 2023.

Based on CVI Holdings's 13F filing for Q3 2023, filed 14 Nov 2023.